<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p197" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_197{left:35px;bottom:24px;letter-spacing:-0.34px;word-spacing:0.13px;}
#t2_197{left:306px;bottom:30px;}
#t3_197{left:313px;bottom:24px;letter-spacing:0.16px;}
#t4_197{left:346px;bottom:30px;}
#t5_197{left:351px;bottom:24px;letter-spacing:-0.16px;word-spacing:-0.22px;}
#t6_197{left:517px;bottom:30px;}
#t7_197{left:524px;bottom:24px;letter-spacing:-0.28px;word-spacing:-0.09px;}
#t8_197{left:288px;bottom:860px;letter-spacing:0.11px;word-spacing:-0.55px;}
#t9_197{left:288px;bottom:829px;letter-spacing:0.27px;word-spacing:-0.69px;}
#ta_197{left:1115px;bottom:27px;letter-spacing:0.23px;}
#tb_197{left:35px;bottom:777px;letter-spacing:0.12px;word-spacing:0.07px;}
#tc_197{left:35px;bottom:754px;letter-spacing:0.11px;word-spacing:-0.38px;}
#td_197{left:35px;bottom:731px;letter-spacing:0.12px;word-spacing:0.08px;}
#te_197{left:409px;bottom:731px;letter-spacing:0.16px;word-spacing:0.02px;}
#tf_197{left:528px;bottom:731px;letter-spacing:0.17px;word-spacing:0.01px;}
#tg_197{left:35px;bottom:707px;letter-spacing:0.1px;word-spacing:-0.85px;}
#th_197{left:35px;bottom:684px;letter-spacing:0.06px;word-spacing:0.13px;}
#ti_197{left:35px;bottom:661px;letter-spacing:0.14px;word-spacing:-0.57px;}
#tj_197{left:148px;bottom:661px;letter-spacing:0.16px;word-spacing:-1.21px;}
#tk_197{left:264px;bottom:661px;letter-spacing:0.09px;word-spacing:-0.61px;}
#tl_197{left:35px;bottom:638px;letter-spacing:0.09px;}
#tm_197{left:110px;bottom:645px;letter-spacing:0.1px;}
#tn_197{left:35px;bottom:599px;letter-spacing:0.12px;word-spacing:-0.4px;}
#to_197{left:35px;bottom:575px;letter-spacing:0.03px;word-spacing:-0.77px;}
#tp_197{left:332px;bottom:575px;letter-spacing:0.24px;word-spacing:-0.87px;}
#tq_197{left:548px;bottom:575px;letter-spacing:0.17px;word-spacing:0.01px;}
#tr_197{left:35px;bottom:552px;letter-spacing:0.11px;word-spacing:0.09px;}
#ts_197{left:400px;bottom:560px;letter-spacing:-0.01px;}
#tt_197{left:35px;bottom:509px;letter-spacing:-0.19px;word-spacing:2.48px;}
#tu_197{left:35px;bottom:481px;letter-spacing:-0.03px;word-spacing:0.33px;}
#tv_197{left:35px;bottom:458px;letter-spacing:0.07px;word-spacing:0.12px;}
#tw_197{left:35px;bottom:435px;letter-spacing:0.13px;word-spacing:0.06px;}
#tx_197{left:439px;bottom:442px;letter-spacing:-0.01px;}
#ty_197{left:462px;bottom:435px;letter-spacing:-0.04px;word-spacing:0.23px;}
#tz_197{left:35px;bottom:412px;word-spacing:0.18px;}
#t10_197{left:35px;bottom:388px;letter-spacing:0.07px;word-spacing:0.12px;}
#t11_197{left:35px;bottom:365px;letter-spacing:-0.04px;word-spacing:0.09px;}
#t12_197{left:35px;bottom:342px;letter-spacing:0.07px;word-spacing:-1.11px;}
#t13_197{left:35px;bottom:319px;letter-spacing:0.06px;word-spacing:0.13px;}
#t14_197{left:35px;bottom:295px;letter-spacing:-0.04px;word-spacing:0.22px;}
#t15_197{left:35px;bottom:272px;letter-spacing:0.04px;word-spacing:0.15px;}
#t16_197{left:35px;bottom:249px;letter-spacing:0.13px;word-spacing:0.06px;}
#t17_197{left:35px;bottom:226px;letter-spacing:0.01px;word-spacing:0.58px;}
#t18_197{left:253px;bottom:233px;letter-spacing:-0.01px;}
#t19_197{left:276px;bottom:226px;letter-spacing:0.05px;word-spacing:0.14px;}
#t1a_197{left:35px;bottom:203px;letter-spacing:0.1px;word-spacing:-0.46px;}
#t1b_197{left:35px;bottom:179px;letter-spacing:0.05px;word-spacing:0.13px;}
#t1c_197{left:35px;bottom:156px;letter-spacing:-0.02px;word-spacing:0.21px;}
#t1d_197{left:233px;bottom:164px;letter-spacing:0.61px;}
#t1e_197{left:248px;bottom:156px;letter-spacing:0.21px;}
#t1f_197{left:310px;bottom:164px;letter-spacing:-0.01px;}
#t1g_197{left:35px;bottom:117px;letter-spacing:0.2px;}
#t1h_197{left:35px;bottom:88px;letter-spacing:0.03px;word-spacing:-0.47px;}
#t1i_197{left:35px;bottom:64px;letter-spacing:0.1px;word-spacing:-1.14px;}
#t1j_197{left:264px;bottom:72px;letter-spacing:-0.21px;}
#t1k_197{left:308px;bottom:64px;letter-spacing:0.17px;word-spacing:0.01px;}
#t1l_197{left:618px;bottom:777px;letter-spacing:0.09px;word-spacing:-0.04px;}
#t1m_197{left:618px;bottom:754px;letter-spacing:0.18px;word-spacing:-0.35px;}
#t1n_197{left:618px;bottom:731px;letter-spacing:0.09px;word-spacing:-1.14px;}
#t1o_197{left:618px;bottom:707px;letter-spacing:0.19px;word-spacing:-0.01px;}
#t1p_197{left:618px;bottom:684px;letter-spacing:0.13px;word-spacing:0.05px;}
#t1q_197{left:931px;bottom:692px;letter-spacing:-0.01px;}
#t1r_197{left:955px;bottom:684px;letter-spacing:0.17px;word-spacing:0.01px;}
#t1s_197{left:618px;bottom:661px;letter-spacing:0.09px;word-spacing:-0.77px;}
#t1t_197{left:618px;bottom:638px;letter-spacing:0.22px;word-spacing:-0.03px;}
#t1u_197{left:618px;bottom:614px;letter-spacing:0.13px;word-spacing:0.06px;}
#t1v_197{left:618px;bottom:591px;letter-spacing:0.12px;word-spacing:-1.05px;}
#t1w_197{left:618px;bottom:568px;letter-spacing:0.08px;word-spacing:0.1px;}
#t1x_197{left:618px;bottom:545px;letter-spacing:0.17px;word-spacing:0.02px;}
#t1y_197{left:618px;bottom:506px;letter-spacing:0.13px;word-spacing:0.06px;}
#t1z_197{left:618px;bottom:482px;letter-spacing:0.17px;word-spacing:-0.73px;}
#t20_197{left:618px;bottom:459px;letter-spacing:0.09px;word-spacing:0.09px;}
#t21_197{left:618px;bottom:436px;letter-spacing:0.15px;word-spacing:0.04px;}
#t22_197{left:618px;bottom:413px;letter-spacing:0.12px;word-spacing:0.06px;}
#t23_197{left:1128px;bottom:420px;letter-spacing:-0.01px;}
#t24_197{left:618px;bottom:390px;letter-spacing:0.2px;word-spacing:-0.02px;}
#t25_197{left:618px;bottom:366px;word-spacing:0.19px;}
#t26_197{left:1082px;bottom:374px;letter-spacing:0.1px;}
#t27_197{left:618px;bottom:343px;letter-spacing:0.18px;word-spacing:0.01px;}
#t28_197{left:618px;bottom:320px;letter-spacing:0.05px;word-spacing:-0.82px;}
#t29_197{left:618px;bottom:297px;letter-spacing:0.04px;word-spacing:0.15px;}
#t2a_197{left:618px;bottom:273px;letter-spacing:0.17px;word-spacing:0.02px;}
#t2b_197{left:618px;bottom:250px;letter-spacing:0.14px;word-spacing:0.05px;}
#t2c_197{left:618px;bottom:210px;letter-spacing:0.1px;word-spacing:0.09px;}
#t2d_197{left:618px;bottom:187px;letter-spacing:0.11px;word-spacing:-0.41px;}
#t2e_197{left:618px;bottom:163px;letter-spacing:0.17px;word-spacing:0.02px;}
#t2f_197{left:933px;bottom:171px;letter-spacing:0.12px;}
#t2g_197{left:1000px;bottom:163px;letter-spacing:0.01px;word-spacing:0.18px;}
#t2h_197{left:618px;bottom:140px;letter-spacing:0.16px;word-spacing:0.04px;}
#t2i_197{left:618px;bottom:117px;letter-spacing:0.12px;word-spacing:-0.46px;}
#t2j_197{left:1106px;bottom:125px;letter-spacing:0.12px;}
#t2k_197{left:1168px;bottom:117px;}
#t2l_197{left:618px;bottom:94px;letter-spacing:0.1px;word-spacing:0.09px;}
#t2m_197{left:1071px;bottom:101px;letter-spacing:-0.01px;}
#t2n_197{left:1094px;bottom:94px;letter-spacing:0.22px;}
#t2o_197{left:618px;bottom:71px;letter-spacing:0.04px;word-spacing:0.28px;}
#t2p_197{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_197{font-size:10px;font-family:ArialMT_5tg;color:#000;}
.s1_197{font-size:6px;font-family:ArialMT_5tg;color:#000;}
.s2_197{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s3_197{font-size:17px;font-family:Arial-BoldMT_5te;color:#000;}
.s4_197{font-size:17px;font-family:ArialMT_5tg;color:#000;}
.s5_197{font-size:17px;font-family:Arial-ItalicMT_kb;color:#000;}
.s6_197{font-size:11px;font-family:ArialMT_5tg;color:#000;}
.s7_197{font-size:20px;font-family:Arial-BoldMT_5te;color:#000;}
.s8_197{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts197" type="text/css" >

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: Arial-ItalicMT_kb;
	src: url("fonts/Arial-ItalicMT_kb.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

</style>
<div id="pg197Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg197" style="-webkit-user-select: none;"><object width="1210" height="935" data="197/197.svg" type="image/svg+xml" id="pdf197" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_197" class="t s0_197">Version 4.2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t2_197" class="t s1_197">© </span>
<span id="t3_197" class="t s0_197">(NCCN </span>
<span id="t4_197" class="t s1_197">© </span>
<span id="t5_197" class="t s0_197">), All rights reserved. NCCN Guidelines </span>
<span id="t6_197" class="t s1_197">® </span>
<span id="t7_197" class="t s0_197">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="t8_197" class="t s2_197">NCCN Guidelines Version 4.2024 </span>
<span id="t9_197" class="t s2_197">Head and Neck Cancers </span>
<span id="ta_197" class="t s3_197">MS-56 </span>
<span id="tb_197" class="t s4_197">H&amp;N examinations. Postoperative RT or consideration of concurrent </span>
<span id="tc_197" class="t s4_197">chemoradiation (category 2B for chemoradiation) is recommended for N2 </span>
<span id="td_197" class="t s4_197">or N3 disease without extranodal extension (see </span><span id="te_197" class="t s5_197">Occult Primary </span><span id="tf_197" class="t s4_197">in the </span>
<span id="tg_197" class="t s4_197">NCCN Guidelines for Head and Neck Cancers). For extranodal extension, </span>
<span id="th_197" class="t s4_197">concurrent chemoradiation is a category 1 recommendation; RT alone is </span>
<span id="ti_197" class="t s4_197">an option (see </span><span id="tj_197" class="t s5_197">Occult Primary </span><span id="tk_197" class="t s4_197">in the NCCN Guidelines for Head and Neck </span>
<span id="tl_197" class="t s4_197">Cancers). </span>
<span id="tm_197" class="t s6_197">134,135 </span>
<span id="tn_197" class="t s4_197">Definitive and postoperative treatment of EBV-positive disease should be </span>
<span id="to_197" class="t s4_197">treated as nasopharyngeal cancer (see </span><span id="tp_197" class="t s5_197">Cancer of the Nasopharynx </span><span id="tq_197" class="t s4_197">in the </span>
<span id="tr_197" class="t s4_197">NCCN Guidelines for Head and Neck Cancers). </span>
<span id="ts_197" class="t s6_197">688 </span>
<span id="tt_197" class="t s7_197">Salivary Gland Tumors </span>
<span id="tu_197" class="t s4_197">Salivary gland tumors can arise in the major salivary glands (ie, parotid, </span>
<span id="tv_197" class="t s4_197">submandibular, sublingual) or in one of the minor salivary glands, which </span>
<span id="tw_197" class="t s4_197">are widely spread throughout the aerodigestive tract. </span>
<span id="tx_197" class="t s6_197">689 </span>
<span id="ty_197" class="t s4_197">Many minor </span>
<span id="tz_197" class="t s4_197">salivary gland tumors are located on the hard palate. Approximately 20% </span>
<span id="t10_197" class="t s4_197">of the parotid gland tumors are malignant; the incidence of malignancy in </span>
<span id="t11_197" class="t s4_197">submandibular and minor salivary gland tumors is approximately 50% and </span>
<span id="t12_197" class="t s4_197">80%, respectively. These malignant tumors constitute a broad spectrum of </span>
<span id="t13_197" class="t s4_197">histologic types, including mucoepidermoid, acinic, adenocarcinoma, </span>
<span id="t14_197" class="t s4_197">adenoid cystic carcinoma, malignant myoepithelial tumors, and squamous </span>
<span id="t15_197" class="t s4_197">cell carcinoma. The primary diagnosis of squamous cell carcinoma of the </span>
<span id="t16_197" class="t s4_197">parotid gland is rare; however, the parotid gland is a frequent site of </span>
<span id="t17_197" class="t s4_197">metastasis from skin cancer. </span>
<span id="t18_197" class="t s6_197">690 </span>
<span id="t19_197" class="t s4_197">Prognosis and tendency to metastasize </span>
<span id="t1a_197" class="t s4_197">vary among these histologic types. Major prognostic factors are histologic </span>
<span id="t1b_197" class="t s4_197">grade, tumor size, and local invasion. Staging is done using the AJCC </span>
<span id="t1c_197" class="t s4_197">Cancer Staging Manual (8 </span>
<span id="t1d_197" class="t s6_197">th </span>
<span id="t1e_197" class="t s4_197">edition). </span>
<span id="t1f_197" class="t s6_197">391 </span>
<span id="t1g_197" class="t s3_197">Treatment </span>
<span id="t1h_197" class="t s4_197">The major therapeutic approach for salivary gland tumors is adequate and </span>
<span id="t1i_197" class="t s4_197">appropriate surgical resection. </span>
<span id="t1j_197" class="t s6_197">691-694 </span>
<span id="t1k_197" class="t s4_197">Surgical intervention requires careful </span>
<span id="t1l_197" class="t s4_197">planning and execution, particularly in parotid tumor surgery because the </span>
<span id="t1m_197" class="t s4_197">facial nerve is in the gland. The gland should be preserved if the nerve is </span>
<span id="t1n_197" class="t s4_197">not directly involved by the tumor. Most parotid gland tumors are located in </span>
<span id="t1o_197" class="t s4_197">the superficial lobe. If the facial nerve is functioning preoperatively, the </span>
<span id="t1p_197" class="t s4_197">nerve can be preserved in most patients. </span>
<span id="t1q_197" class="t s6_197">695 </span>
<span id="t1r_197" class="t s4_197">The facial nerve should be </span>
<span id="t1s_197" class="t s4_197">sacrificed if there is preoperative facial nerve involvement with facial palsy </span>
<span id="t1t_197" class="t s4_197">or if there is direct invasion of the tumor into the nerve where the tumor </span>
<span id="t1u_197" class="t s4_197">cannot be separated from the nerve. Malignant deep lobe parotid tumors </span>
<span id="t1v_197" class="t s4_197">are rare; however, they are generally a challenge for the surgeon because </span>
<span id="t1w_197" class="t s4_197">the patient may require superficial parotidectomy and identification and </span>
<span id="t1x_197" class="t s4_197">retraction of the facial nerve to remove the deep lobe parotid tumor. </span>
<span id="t1y_197" class="t s4_197">The panel recommends highly conformal RT techniques such as IMRT, </span>
<span id="t1z_197" class="t s4_197">proton, or other heavy ions for definitive radiation treatment. Results from </span>
<span id="t20_197" class="t s4_197">a retrospective cohort study including 545 patients with salivary gland </span>
<span id="t21_197" class="t s4_197">tumors treated between 1997 and 2010 showed better local control and </span>
<span id="t22_197" class="t s4_197">survival outcomes with neutron therapy, relative to photon therapy. </span>
<span id="t23_197" class="t s6_197">696 </span>
<span id="t24_197" class="t s4_197">However, risk of late effects with neutron therapy is high and tends to </span>
<span id="t25_197" class="t s4_197">increase over time, with estimates as high as 20% at 9 years. </span>
<span id="t26_197" class="t s6_197">697,698 </span>
<span id="t27_197" class="t s4_197">Neutron therapy is no longer routinely recommended for treatment of </span>
<span id="t28_197" class="t s4_197">salivary gland cancers due to the diminishing demand, concerns regarding </span>
<span id="t29_197" class="t s4_197">the methodologic robustness of available randomized trial data, and </span>
<span id="t2a_197" class="t s4_197">closure of all but one center in the United States. The panel recognizes </span>
<span id="t2b_197" class="t s4_197">the potential clinical value of neutron therapy for select patients. </span>
<span id="t2c_197" class="t s4_197">Most malignant deep lobe parotid tumors will require postoperative RT </span>
<span id="t2d_197" class="t s4_197">because of adverse pathologic features such as the limitations of surgical </span>
<span id="t2e_197" class="t s4_197">margins in the resection of these tumors. </span>
<span id="t2f_197" class="t s6_197">691,693,699 </span>
<span id="t2g_197" class="t s4_197">RT is also used in an </span>
<span id="t2h_197" class="t s4_197">adjuvant setting for tumors with other adverse pathologic features (eg, </span>
<span id="t2i_197" class="t s4_197">intermediate, high-grade, T3–4 tumors, or positive lymph nodes) </span>
<span id="t2j_197" class="t s6_197">692,700,701 </span>
<span id="t2k_197" class="t s4_197">; </span>
<span id="t2l_197" class="t s4_197">systemic therapy/RT (category 2B) can also be considered. </span>
<span id="t2m_197" class="t s6_197">702 </span>
<span id="t2n_197" class="t s4_197">Efficacy </span>
<span id="t2o_197" class="t s4_197">data for systemic therapy/RT for patients with advanced salivary gland </span>
<span id="t2p_197" class="t s8_197">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
